Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.375
Bid: 7.25
Ask: 7.50
Change: 0.00 (0.00%)
Spread: 0.25 (3.448%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 7.375
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TSB Grant to Develop Dementia Diagnosis Products

13 Dec 2013 07:00

RNS Number : 4517V
IXICO plc
13 December 2013
 



 

IXICO Awarded Technology Strategy Board Grant to Support the Development of Dementia Diagnosis Products

 

13 December 2013, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announces that it has been awarded a Stratified Medicine Grant by the UK's innovation agency, the Technology Strategy Board to provide funding to support the development of products to address the global dementia challenge.

 

The grant has been awarded under the Technology Strategy Board's recently launched 'Advancing In-Vivo Imaging for Stratified Medicine' competition. 

 

For this project, a consortium led by IXICO, which includes Imperial College, London as a research partner, Medimmune Limited (the global biologics research and development arm of AstraZeneca) and a second leading global pharmaceutical company as commercial partners, will apply a machine learning framework to a unique combination of reference data to develop a digital dementia prognosis tool. This will use commonly collected diagnostic information (including MRI scans and cognitive, functional and demographic data) to stratify patients based on their expected rate of decline. This could help with the diagnosis of dementia in the clinic and also with the enrichment of patient populations enrolled in clinical trials of investigational drugs, potentially improving the likelihood of measuring a therapeutic effect.

 

Several further global pharmaceutical companies have expressed interest joining the project as collaborators, and contributing clinical trial data in due course. The total value of the 24 month research project is approximately £1 million. The value of the grant is £633,962 of which £456,956 is allocated to IXICO and the remainder to Imperial College. The pharmaceutical partners and collaborators are contributing scientific resources from their R&D teams and access to data from completed clinical trials.

 

This brings the total grant funding secured by IXICO in the last 18 months to approximately £2.6 million of which approximately £2.4 million remains to be drawn down by IXICO.

 

This week the Technology Strategy Board features IXICO, the "Dementia Champions", as its Success Story www.innovateuk.org/success-stories detailing a funding story that stretches back 5 years.

 

Professor Derek Hill, Chief Executive of IXICO commented: "We are pleased to have been awarded this Technology Strategy Board grant. IXICO's products and services are focused on three overlapping areas within clinical trials, experimental medicine and diagnostics; the scope of this project will benefit our work in each. We look forward to working with Imperial and our commercial collaborators to develop important tools with the potential to improve clinical diagnosis of dementia and accelerate the development of effective treatments for Alzheimer's disease."

 

 

Enquiries

 

IXICO plc

+44 207 691 2064

Derek Hill, CEO

Charles Spicer, VP Corporate Development

 

Peel Hunt LLP (Nominated Adviser and broker)

+44 207 418 8900

James Steel

Vijay Barathan

Harry Florry

 

FTI Consulting Limited (U.K. Investor Relations)

+44 207 831 3113

John Dineen

Simon Conway

 

 

About IXICO

IXICO, the brain health company, was founded in 2004 with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products targeting the expanding area of imaging to inform decision-making during drug development. This has resulted in commercially successful products being launched in the clinical trials (Phase 0-III) and experimental medicine markets and being readied for launch into the wider clinical diagnostic market. Since incorporation, IXICO has been contracted by seven of the top 15 global pharmaceutical companies as well as leading biotechnology companies. In October 2013, IXICO plc was admitted to trading on AIM. More information is available on www.ixico.com

 

About the Technology Strategy Board

The Technology Strategy Board is the UK's innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKMMMZZZRGFZZ
Date   Source Headline
30th Apr 20157:49 amRNSLaunch of dementia care digital platform
24th Apr 20157:00 amRNSNew contract in Huntington's disease
11th Mar 20157:00 amRNSVirtualScopics, IXICO and Micron in collaboration
6th Mar 201511:38 amRNSResult of AGM
10th Feb 20154:25 pmRNSReplacement - Financial Results
10th Feb 20157:00 amRNSResults for the 16 month period ended 30 Sept 2014
16th Jan 20157:00 amRNSIXICO selected as EPAD imaging analysis partner
16th Dec 20147:00 amRNSLicense of TrialTracker to VirtualScopics
26th Nov 20147:00 amRNSAnnouncement of enhanced contracts
29th Oct 20147:30 amRNSGrant of Awards to Directors
17th Sep 20147:00 amRNSAppointment of Chief Financial Officer
7th Aug 20147:00 amRNSAdditional Listing
31st Jul 20144:19 pmRNSHolding(s) in Company
21st Jul 20144:33 pmRNSDirector/PDMR Shareholding
18th Jul 20147:00 amRNSTrading Update
19th Jun 20147:00 amRNSCollaboration with the MRC for dementia research
6th Jun 20147:00 amRNSHalf Yearly Report
22nd May 20147:00 amRNSTwo contracts in Huntington's disease awarded
30th Apr 20142:58 pmRNSHolding(s) in Company
16th Apr 20147:00 amRNSIXICO plc announces SBRI Healthcare contract
20th Mar 201412:41 pmRNSResults of AGM
11th Mar 20142:43 pmRNSDirector/PDMR Shareholding
11th Mar 201410:04 amRNSHolding(s) in Company
7th Mar 20142:35 pmRNSInternational alliance with VirtualScopics
28th Feb 20147:00 amRNSPublication of annual report and business update
6th Feb 20147:00 amRNSAppointment of Joint Broker
13th Jan 20149:51 amRNSPresents at Dementia Challenge seminar in Beijing
2nd Jan 20145:08 pmRNSHolding(s) in Company
17th Dec 20137:00 amRNSBusiness and trading update
13th Dec 20137:00 amRNSTSB Grant to Develop Dementia Diagnosis Products
11th Dec 20137:00 amRNSDementia diagnosis tool launch and InHealth update
10th Dec 20137:00 amRNSAttending G8 Global CEO Initiative on Alzheimer's
2nd Dec 201310:03 amRNSIXICO signs MOU with Beijing UMP
18th Nov 20136:00 pmRNSDirector/PDMR Shareholding
1st Nov 20134:01 pmRNSDirector/PDMR Shareholding
31st Oct 201311:26 amRNSDirector/PDMR Shareholding
22nd Oct 201312:29 pmRNSHolding(s) in Company
21st Oct 20131:22 pmRNSDirector/PDMR Shareholding
17th Oct 20133:08 pmRNSHolding(s) in Company
15th Oct 20137:00 amRNSFirst Day of Dealings
14th Oct 201312:18 pmRNSResult of General Meeting
14th Oct 201311:08 amRNSSchedule 1 update - Phytopharm Plc
11th Oct 20131:48 pmRNSSch 1 Update - Phytopharm plc
3rd Oct 20139:23 amRNSHolding(s) in Company
1st Oct 20137:00 amRNSDirector/PDMR Shareholding
30th Sep 20132:45 pmRNSSchedule 1 - Phytopharm Plc
27th Sep 20133:17 pmRNSDirector/PDMR Shareholding
24th Sep 20137:30 amRNSRestoration - Phytopharm Plc
23rd Sep 20137:05 amRNSIXICO expands into digital healthcare
23rd Sep 20137:00 amRNSProposed acquisition of IXICO Limited

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.